

REMARKS

The specification has been amended to reflect the national stage status.

In addition, the specification and claims have been amended to correct a minor typographical error.

Lastly, the use claims 15-16 have been rewritten in conformance with U.S. practice and claim 17 is cancelled without prejudice.

Support for the "pharmaceutically acceptable carrier" is found in the specification at page 56, line 8.

Favorable action on the merits is solicited.

Respectfully submitted,

Tsuneo YASUMA et al.

By



Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 23, 2006